Shattuck Labs, Inc. (STTK)

NASDAQ: STTK · Real-Time Price · USD
1.550
+0.040 (2.65%)
At close: Sep 5, 2025, 4:00 PM
1.540
-0.010 (-0.65%)
After-hours: Sep 5, 2025, 7:50 PM EDT
2.65%
Market Cap74.25M
Revenue (ttm)3.00M
Net Income (ttm)-61.51M
Shares Out 47.90M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,448,510
Open1.510
Previous Close1.510
Day's Range1.450 - 1.565
52-Week Range0.692 - 3.950
Beta1.65
AnalystsHold
Price Target2.00 (+29.03%)
Earnings DateAug 14, 2025

About STTK

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involv... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 44
Stock Exchange NASDAQ
Ticker Symbol STTK
Full Company Profile

Financial Performance

In 2024, Shattuck Labs's revenue was $5.72 million, an increase of 245.26% compared to the previous year's $1.66 million. Losses were -$75.41 million, -13.62% less than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for STTK stock is "Hold." The 12-month stock price target is $2.0, which is an increase of 29.03% from the latest price.

Price Target
$2.0
(29.03% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disea...

11 days ago - GlobeNewsWire

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –

16 days ago - GlobeNewsWire

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

23 days ago - GlobeNewsWire

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –

4 weeks ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

2 months ago - GlobeNewsWire

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 –...

4 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor ne...

5 months ago - GlobeNewsWire

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-cla...

5 months ago - GlobeNewsWire

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxic...

7 months ago - GlobeNewsWire

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necro...

7 months ago - GlobeNewsWire

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

7 months ago - GlobeNewsWire

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

8 months ago - GlobeNewsWire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

8 months ago - GlobeNewsWire

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

11 months ago - Accesswire

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

The stock hit a low of $1.37 earlier in the session, matching its record closing low that was set in October 2023.

1 year ago - Market Watch

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvem...

1 year ago - GlobeNewsWire